Considering the well-established role of alkylation repair in chemoresistance [7], inhibition of USP7 represents a highly attractive therapeutic strategy to overcome chemoresistance in GBM and other malignancies, potentially facilitating the use of combination therapies with various alkylating agents, including TMZ. The gene discussed is USP7; the disease is glioblastoma.